Switch theme
Sign up to access all valuation multiples
CStone Pharmaceuticals is engaged in the development and commercialization of tumor immunotherapy and molecular-targeted drugs. It has been operating in one reportable segment, the research and development of complex biopharmaceutical products.
2015
230
LTM Revenue $58.7M
LTM EBITDA -$19.7M
$422M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
CStone Pharmaceuticals has a last 12-month revenue of $58.7M and a last 12-month EBITDA of -$19.7M.
In the most recent fiscal year, CStone Pharmaceuticals achieved revenue of $59.7M and an EBITDA of -$38.2M.
CStone Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See CStone Pharmaceuticals valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $61.9M | $59.7M | XXX | XXX | XXX |
| Gross Profit | $17.6M | $35.8M | XXX | XXX | XXX |
| Gross Margin | 28% | 60% | XXX | XXX | XXX |
| EBITDA | -$109M | -$38.2M | XXX | XXX | XXX |
| EBITDA Margin | -177% | -64% | XXX | XXX | XXX |
| Net Profit | -$247M | -$116M | XXX | XXX | XXX |
| Net Margin | -399% | -195% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, CStone Pharmaceuticals's stock price is HKD 3 (or $0).
CStone Pharmaceuticals has current market cap of HKD 3.6B (or $465M), and EV of HKD 3.3B (or $422M).
See CStone Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $422M | $465M | XXX | XXX | XXX | XXX | $-0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, CStone Pharmaceuticals has market cap of $465M and EV of $422M.
CStone Pharmaceuticals's trades at 7.7x LTM EV/Revenue multiple, and -23.0x LTM EBITDA.
Analysts estimate CStone Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for CStone Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $422M | XXX | XXX | XXX |
| EV/Revenue | 7.1x | XXX | XXX | XXX |
| EV/EBITDA | -11.0x | XXX | XXX | XXX |
| P/E | -9.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -5.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCStone Pharmaceuticals's NTM/LTM revenue growth is 12%
CStone Pharmaceuticals's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $0.5M for the same period.
Over next 12 months, CStone Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate CStone Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for CStone Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -4% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -64% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -65% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -52% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.3M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 43% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 11% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 114% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 191% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CStone Pharmaceuticals acquired XXX companies to date.
Last acquisition by CStone Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . CStone Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was CStone Pharmaceuticals founded? | CStone Pharmaceuticals was founded in 2015. |
| Where is CStone Pharmaceuticals headquartered? | CStone Pharmaceuticals is headquartered in Hong Kong. |
| How many employees does CStone Pharmaceuticals have? | As of today, CStone Pharmaceuticals has 230 employees. |
| Who is the CEO of CStone Pharmaceuticals? | CStone Pharmaceuticals's CEO is Dr. Jianxin Yang, M.D.,PhD. |
| Is CStone Pharmaceuticals publicy listed? | Yes, CStone Pharmaceuticals is a public company listed on HKG. |
| What is the stock symbol of CStone Pharmaceuticals? | CStone Pharmaceuticals trades under 02616 ticker. |
| When did CStone Pharmaceuticals go public? | CStone Pharmaceuticals went public in 2019. |
| Who are competitors of CStone Pharmaceuticals? | Similar companies to CStone Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of CStone Pharmaceuticals? | CStone Pharmaceuticals's current market cap is $465M |
| What is the current revenue of CStone Pharmaceuticals? | CStone Pharmaceuticals's last 12-month revenue is $58.7M. |
| What is the current EBITDA of CStone Pharmaceuticals? | CStone Pharmaceuticals's last 12-month EBITDA is -$19.7M. |
| What is the current EV/Revenue multiple of CStone Pharmaceuticals? | Current revenue multiple of CStone Pharmaceuticals is 7.7x. |
| What is the current EV/EBITDA multiple of CStone Pharmaceuticals? | Current EBITDA multiple of CStone Pharmaceuticals is -23.0x. |
| What is the current revenue growth of CStone Pharmaceuticals? | CStone Pharmaceuticals revenue growth between 2023 and 2024 was -4%. |
| Is CStone Pharmaceuticals profitable? | Yes, CStone Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
